Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1582-1586

  Imielinski, Marcin ^a,b,c   Greulich, Heidi ^b,c,d   Kaplan, Bethany ^b,c   Araujo, Luiz ^e   Amann, Joseph ^e   Horn, Leora ^f   Schiller, Joan ^g   Villalona Calero, Miguel A ^e   Meyerson, Matthew ^b,c,d   Carbone, David P ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARAF PROTEIN; B RAF KINASE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; GEFITINIB; GEMCITABINE; NAVELBINE; ONCOPROTEIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN RET; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ARTICLE; BLOOD; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; CELL IMMORTALIZATION; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPITHELIUM CELL; FATIGUE; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HOSPICE CARE; HUMAN; HUMAN TISSUE; HYPOXIA; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG LOBE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY EPITHELIUM; RNA SEQUENCE; SAMPLE; SMOKING; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE;

ADENOCARCINOMA; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NIACINAMIDE; ONCOGENES; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 84897562716     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72763     Document Type: Article

References (21)

1. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol. 2013;31(15):1858-1865.
2. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1097-1104.
3. Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-1120.
4. Iyer G, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.
5. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1039-1045.
6. Wilhelm S, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835-844. (Pubitemid 44480537)
7. Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012;7(10):1574-1582.
8. Weir BA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-898. (Pubitemid 350231325)
9. Ding L, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
10. Kan Z, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869-873.
11. Govindan R, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121-1134.
12. Ramos AH, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009;8(21):2042-2050.
13. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875-885. (Pubitemid 39486539)
14. Pandit B, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-1012. (Pubitemid 47185177)
15. Awada A, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92(10):1855-1861. (Pubitemid 40826133)
16. Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
17. Druker BJ, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
18. Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013;73(15):4840-4851.
19. Abraham D, et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem. 2000;275(29):22300-22304. (Pubitemid 30621814)
20. Dingemans AM, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res. 2013;19(3):743-751.
21. Greulich H, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012;109(36):14476-14481.